Naples Soap Company Launches Celestii™: A NASA‑Backed, 3‑D Stem Cell Skincare Line Promising Clinical Results

Key Highlights:
Introduction
How a Zero‑Gravity Bioreactor Became a Cosmetic Ingredient Factory
What “3‑D Stem Cells” and “Biomimetic Suspensions” Mean for Skin
The Face Serum’s Formulation: Polyglutamic Acid, Hyaluronic Complexes and Botanical Actives
Decoding the Clinical Claims: What the AMA Laboratories Study Shows—and What It Doesn’t
Safety, Regulation and Ethical Considerations for Stem Cell‑Inspired Cosmetics
Where Celestii Fits in the Broader Biotech Beauty Landscape
Practical Use: How Consumers Might Incorporate Celestii Face Serum
Business Implications for Naples Soap Company and Investors
Comparing Celestii with Existing Alternatives: What’s New and What’s Familiar
Questions to Ask Before Buying: A Consumer Checklist
Real‑World Examples and Early Adopter Response
What Dermatologists and Scientists Will Likely Want to See
A Note on Language and Marketing: Reading Between the Lines
Final Observations on Potential and Prudence
FAQ

Key Highlights:

Naples Soap Company introduced Celestii™, a premium skincare line built around 3‑D stem cells cultured in a biomimetic suspension using zero‑gravity bioreactor technology originally developed by NASA.
The flagship Celestii™ Face Serum combines polyglutamic acid, multi‑molecular hyaluronic complexes and the proprietary 3‑D cell suspension; a controlled study by AMA Laboratories reported up to 161% increased hydration, 42% improved firmness/elasticity and up to 57% reduction in dark circles.
The product raises scientific and regulatory questions common to biotech cosmetic launches—clarity on cell sourcing, formulation (live cells vs. cell‑derived factors), study details and long‑term safety will determine consumer trust and market impact.

Introduction

A Florida-based bath-and-body brand is staking its future on laboratory-grown biology. Naples Soap Company has unveiled Celestii™, a premium skincare range centered on three‑dimensional stem cells cultured in a biomimetic suspension using technology modeled on NASA’s zero‑gravity bioreactor. The company positions Celestii as a clinically validated, high‑performance line for mature, dehydrated or environmentally stressed skin, led by a face serum that mixes next‑generation humectants with the brand’s signature cell suspension.

This announcement sits at the intersection of two accelerating trends: the beauty industry’s adoption of biotechnology and consumer demand for measurable outcomes. Celestii’s press materials cite a controlled study showing marked improvements in hydration, firmness and dark circles. The technology behind the claim traces to rotating bioreactor platforms that allow cells to grow three‑dimensionally, a capability that has attracted attention across tissue engineering, regenerative medicine and now cosmetics.

Readers confronting the product will want to know how this NASA‑adjacent technology translates into a jar of serum, what the clinical data actually say, how regulatory oversight applies and whether the molecular benefits hold up under real‑world use. This article parses the science behind Celestii, evaluates the evidence presented to date, places the launch in market context and outlines what consumers and clinicians should look for next.

How a Zero‑Gravity Bioreactor Became a Cosmetic Ingredient Factory

The origin story for Celestii’s core ingredient begins with observations made in microgravity: cells cultured in space tend to form three‑dimensional structures and behave differently than the same cells on a flat surface. The space environment removes the dominant directional cues cells receive under gravity, allowing them to assemble in ways that can better mimic living tissues.

On Earth, that phenomenon is recreated in rotating or “low‑shear” bioreactors that simulate microgravity by keeping cells in continuous suspension. These systems—often described generically as rotating wall vessels or zero‑gravity bioreactors—use carefully controlled rotation and fluid dynamics to prevent cells from settling. The result is three‑dimensional (3‑D) cell aggregates with richer extracellular matrix production and different signaling profiles than two‑dimensional cultures.

For researchers, this has practical implications: 3‑D cultures often express genes, secrete proteins and interact in ways closer to living tissue. In regenerative medicine and drug screening, three‑dimensional cultures provide more realistic models of human biology. Cosmetic developers have taken note because the secreted factors from such cultures—growth factors, cytokines, extracellular matrix proteins and other biomolecules—can be attractive as topical actives. These cell‑secreted cocktails are sometimes called “conditioned media,” “secretomes” or, more broadly, biomimetic suspensions.

Naples Soap Company’s press release links its Celestii technology to that NASA legacy and notes recognition by the Space Technology Hall of Fame for the bioreactor’s contributions to medicine and dermatology. Translating a space‑derived method into a consumer product requires multiple steps—consistent cell sourcing, scalable culture conditions, safety testing, stabilization of the bioactive mixture and formulation into a stable serum—each of which determines whether the biological promise survives until it reaches skin.

What “3‑D Stem Cells” and “Biomimetic Suspensions” Mean for Skin

The terms used in Celestii’s announcement—“3‑D stem cells,” “biomimetic suspension,” “growth factors, cytokines, proteins and other biomolecules”—describe a complex biological product, but the press release leaves critical technical details unspecified. Those omissions matter for assessing safety, efficacy and regulatory status.

3‑D stem cells: This suggests stem cells were cultured in three dimensions rather than on flat plastic. Three‑dimensional growth changes cell behavior and secretion profiles. However, the release does not specify the cell type (e.g., human adult stem cells, umbilical‑derived, allogeneic, autologous, or plant-derived analogues), the species of origin or whether intact (living) cells are present in the final topical product.
Biomimetic suspension: That phrase generally refers to a medium designed to mimic the cellular microenvironment—supporting nutrient exchange, signaling and extracellular matrix formation—and to preserve the secreted molecules. It may describe a stabilized conditioned media that contains proteins and signaling molecules but not viable cells.
Growth factors and cytokines: These are signaling proteins that regulate cell proliferation, inflammation and matrix remodeling. Topically applied growth factors and cytokines can influence skin physiology to some extent, although penetration into deeper skin layers is limited and depends on molecular size, formulation and delivery technology.

A crucial distinction separates a skincare product containing live cells from one containing cell‑derived factors. Live mammalian cells in a cosmetic would raise significant safety, sterility and regulatory complexities, as well as requiring cold‑chain logistics and limited shelf life. Most consumer products that use the language of “stem cells” deploy acellular outputs—conditioned media or secretomes—since these provide bioactive molecules without the hurdles of live cell therapies.

The press release for Celestii uses phrasing that could be interpreted either way. Consumers and clinicians should ask the company whether Celestii products contain viable cells or acellular extracts derived from 3‑D cultured cells, and what measures are in place for sterility, batch testing and stability.

The Face Serum’s Formulation: Polyglutamic Acid, Hyaluronic Complexes and Botanical Actives

Celestii’s flagship Face Serum reportedly blends the proprietary 3‑D cell suspension with other high‑performance actives. Two ingredients highlighted in the release—polyglutamic acid (PGA) and multi‑molecular hyaluronic complexes—address hydration through complementary mechanisms.

Polyglutamic acid (PGA): PGA is a polypeptide often derived from microbial fermentation (e.g., natto fermentation) and valued in skincare as a potent humectant. It binds water on the skin’s surface and has been marketed as offering superior water‑retention compared with hyaluronic acid by weight or via different film‑forming properties. PGA also contributes to a plumping feel and a smoother skin surface.
Multi‑molecular hyaluronic complexes: Hyaluronic acid (HA) exists in multiple molecular weights. Low‑molecular‑weight HA penetrates more superficially and can provide quick surface hydration, while high‑molecular‑weight HA forms a film and retains water at the surface. Using a multi‑molecular approach attempts to hydrate both superficially and within the skin’s upper layers, creating a layered hydration strategy.

Botanical extracts and targeted actives supplement the core humectants and the cell suspension. Botanical actives can offer antioxidant protection and soothe the skin, although botanical mixtures vary widely in composition and potency. The synergy claimed—humectants for retention, cell‑derived factors for signaling and botanicals for protection—represents a modern formulation strategy seen across premium skincare brands.

The serum is described as lightweight and fast absorbing, suitable for daily use under makeup or SPF. For consumers, the practical benefits of such a texture can be decisive: a product that layers well and absorbs quickly is more likely to be used consistently, which ultimately influences outcomes.

Decoding the Clinical Claims: What the AMA Laboratories Study Shows—and What It Doesn’t

Naples Soap Company cites a controlled study by AMA Laboratories reporting the following outcomes for the Celestii Face Serum:

Up to a 161% increase in skin hydration
A 42% improvement in skin firmness and elasticity
As much as a 57% visible reduction in dark circles

Those numbers are headline‑grabbing, but evaluating their significance requires context.

Measurement methods

Hydration increases are typically quantified with instruments such as corneometers or conductance meters that measure the skin’s electrical properties and infer water content. A 161% increase suggests substantial change in measured hydration, but the baseline values and absolute differences are essential to interpret clinical relevance.
Firmness and elasticity often come from cutometer measurements, which quantify the skin’s mechanical response to suction. A 42% improvement could be meaningful, but it depends on the study population, treatment regimen, and measurement timing.
Reduction in dark circles is commonly assessed through standardized photography, colorimetry or clinician/subject visual grading scales. A 57% visible reduction suggests an observable change but depends on lighting, scoring methodology and participant diversity.

Missing details that matter

Sample size and demographics: The press release does not disclose how many subjects participated, their ages, skin types or skin conditions. Results from a small, homogenous group have limited generalizability.
Study duration and application regimen: Improvements measured after a single application versus sustained use over weeks are not equivalent. The release omits whether results were immediate, short‑term or cumulative.
Control conditions and statistical significance: “Controlled” can mean different things—vehicle control, placebo, or untreated skin. The release does not specify whether improvements were statistically significant, the control used, or blinding procedures.
Adverse events and tolerability: Safety data, including irritation rates and patch test results, are not presented in the summary.

How to read the numbers Even with robust methodology, cosmetic clinical endpoints are commonly sensitive to measurement parameters and expectations. Claims of “up to X%” often reflect peak improvements in subgroups or particular timepoints. Independent peer review or publication in a dermatology journal would strengthen the credibility of the findings.

For consumers and clinicians, transparency matters more than marketing language. Naples Soap Company’s clinical claim is notable; the next step for rigorous evaluation is access to the full study protocol, raw data, and independent replication.

Safety, Regulation and Ethical Considerations for Stem Cell‑Inspired Cosmetics

Using stem‑cell‑related technology in skincare raises several safety and regulatory considerations. Consumer products that contain only acellular extracts generally fall under cosmetic regulations, but if a formulation contains viable human cells or is intended to alter skin structure in a way that treats disease, regulators may view it differently.

Regulatory landscape

Cosmetic vs. drug/biologic: Products marketed to clean, moisturize or temporarily alter appearance typically qualify as cosmetics. If a product claims to repair tissue, reverse aging at a cellular level, or deliver therapeutic benefits, regulators may consider it a drug or biologic subject to stricter oversight.
Live cells and sterility: If a topical product includes viable mammalian cells, it would raise complex manufacturing controls—aseptic processing, cold chain, sterility testing and potentially regulatory oversight as a biologic. The press release does not say Celestii contains viable cells; the industry norm is to use conditioned media or stabilized extracts to avoid these hurdles.
Ingredient transparency and labeling: Clear disclosure of cell origin, manufacturing methods and bioactive contents (e.g., concentration of specific growth factors) helps consumers and clinicians assess risk. Without transparency, questions about sourcing, donor consent, and batch variability remain.

Safety and ethical issues

Immunogenicity and contamination: Any biologic product must guard against contamination and unintended immune responses. Even acellular secretomes can include proteins that elicit irritation in sensitive individuals.
Source of stem cells: Ethical concerns arise if cell sources are human embryonic or fetal tissues. Many companies use adult stem cells, induced pluripotent stem cells (iPSCs), or plant/fermentation‑derived analogues to minimize ethical issues, but the press release does not clarify.
Long‑term effects: Topical exposure to growth factors theoretically could influence local cell behavior beyond superficial aesthetics. Longer‑term studies would help define whether sustained use has unanticipated effects.

Practical consumer safeguards

Request full ingredient lists and manufacturing details.
Seek independent data on stability, sterility, and irritation potential.
Consult a dermatologist before combining biotech serums with active prescriptions such as retinoids or medical procedures.

Where Celestii Fits in the Broader Biotech Beauty Landscape

Celestii’s launch is part of a broader shift: beauty brands increasingly partner with biotech and life‑science advances to differentiate premium offerings. Several trends illuminate how Celestii aligns with market movements.

Conditioned media and secretomes Biotech startups and cosmetic brands over the past decade have moved toward “conditioned media” derived from stem cell cultures, claiming that the secreted proteins and peptides support skin renewal. These ingredients are positioned as alternatives to synthetic actives or to invasive procedures, often marketed to consumers seeking clinically backed, scientifically flavored products.

Growth factor products Some legacy brands already use growth factors topically. For instance, epidermal growth factor (EGF) and platelet‑derived growth factors have been formulated into serums and creams. Commercial examples include products that use plant‑expressed EGF or recombinant proteins produced by fermentation.

Microbiome and fermentation science The industry has also embraced fermentation‑derived actives—probiotic lysates, fermented botanicals and microbial exopolysaccharides—which mimic the biochemical complexity of biology without requiring mammalian cell culture.

Space and prestige branding Associating a product with NASA or space‑derived innovation taps into a prestige narrative. Consumers respond to convincing provenance stories; yet brand credibility depends on transparency about how the space technology was adapted, scaled and validated for consumer use.

Market positioning and pricing Premium biotech skincare commands higher price points. Consumers expect clinical evidence and manufacturing transparency in exchange for cost. For a small company like Naples Soap Company, the challenge is demonstrating scientific rigor comparable to specialty biotech brands while maintaining retail accessibility.

Practical Use: How Consumers Might Incorporate Celestii Face Serum

Based on the product description and common skincare practice, here are practical guidelines for consumers considering Celestii Face Serum.

Morning or evening use

The serum’s lightweight, fast‑absorbing profile makes it suitable for both morning and evening routines.
Use under sunscreen during the day; hyaluronic‑ and PGA‑based humectants pair well with SPF.

Layering and compatibility

Apply after cleansing and before thicker moisturizers or oils to maximize absorption of humectants and bioactives.
If using prescription retinoids, consider alternating nights or consult a dermatologist; combining multiple active treatments can increase irritation risk.

Patch testing

Perform a patch test on a small area for 48 hours before full‑face application—especially important for products containing bioactive proteins or botanical extracts.

Expected timelines

Hydration effects may be immediate due to humectants. Improvement in skin firmness and dark circles, if biologically driven, may require weeks of consistent use. Clinical claim details would clarify typical timelines.

Storage and shelf life

If the product contains sensitive proteins, storage recommendations matter. The press release does not specify packaging, cold chain or shelf life. Consumers should check the label for storage instructions and expiration dates.

Suitability

The brand targets mature, dehydrated or environmentally stressed skin. Individuals with eczema, rosacea, or known sensitivity to protein‑rich formulations should consult a dermatologist before use.

Business Implications for Naples Soap Company and Investors

For Naples Soap Company, Celestii represents an attempt to move upmarket and differentiate via science. The company operates 13 retail outlets in Florida and supplies over 400 boutiques and spas nationwide. The NASO ticker on the OTCQB signals that investors will watch whether the biotech positioning translates to sales growth and brand elevation.

Potential upsides

Differentiation: A unique, science‑driven product can create a halo effect for the broader brand.
New distribution opportunities: Dermatology clinics and medical spas may show interest if clinical data are forthcoming.
Investor interest: Biotech associations and clinical claims attract attention from specialized investors who value innovation.

Risks and execution challenges

Credibility hinge: Ambiguity about the scientific details—cell source, viability in product, study design—could limit uptake among discerning consumers and clinicians.
Cost structure: Producing cell‑derived materials at scale is expensive; pricing must reflect costs while fitting market expectations.
Regulatory and litigation risk: Any suggestion of therapeutic claims beyond cosmetic benefits invites regulatory scrutiny and possible enforcement actions if labels overstep cosmetic definitions.

Naples Soap Company’s public disclosure also includes standard forward‑looking statements cautioning that management expectations may not materialize and that risks exist. For market observers, commercial traction and transparent science will determine whether Celestii is a strategic success or a niche experiment.

Comparing Celestii with Existing Alternatives: What’s New and What’s Familiar

Evaluating Celestii requires comparing it against both established humectant serums and emerging biotech formulations.

Similarities with existing products

Humectant strategy: Combining hyaluronic acid with other humectants is commonplace. Many premium serums use multi‑weight HA for layered hydration.
Botanical extracts: Antioxidant‑rich botanicals appear across high‑end skincare.
Clinical claims: Brands often support marketing with in‑house or third‑party lab studies, reporting percentage improvements on hydration and elasticity.

Differentiators

3‑D stem cell suspension: The central differentiator is the use of factors derived from cells cultured in a zero‑gravity bioreactor. If the product contains a unique constellation of growth factors and cytokines not found in standard extracts, it could provide distinct biological signaling.
NASA technology association: Backing the formulation with a narrative linked to NASA’s bioreactor technology adds prestige and novelty.
Reported clinical magnitudes: If the study methodology checks out, the magnitude of hydration and firmness improvements reported would outpace many conventional serums.

Existing brand examples

Bioeffect: Uses plant‑derived EGF expressed in barley for targeted signaling.
Other conditioned media products: Several niche brands offer serums formulated with stem cell‑derived conditioned media—often plant‑ or human‑cell‑sourced—aiming to harness secreted proteins while avoiding live cell issues.

Ultimately, whether Celestii stands apart will depend on transparency, reproducibility of clinical outcomes and real‑world user experience.

Questions to Ask Before Buying: A Consumer Checklist

When evaluating any biotech‑framed skincare product—Celestii included—consumers should consider the following:

What exactly is in the product? Request a full ingredient list and clarification on whether the product contains viable cells or acellular extracts.
Who performed the clinical testing? Ask for the full study report: number of participants, controls used, duration, statistical significance and adverse events.
How is the product manufactured and tested for safety? Seek information on sterility testing, batch release criteria and storage conditions.
What is the provenance of the cells? Clarify whether cells are human, animal, or plant‑derived and whether donor consent and ethical sourcing policies are in place.
How reproducible are results? Look for independent reviews, dermatologist commentary and third‑party testing.
What is the price per treatment course? Compare cost against efficacy and competing products that offer clinically documented benefits.
How should the serum fit into an existing routine? Verify compatibility with prescription actives and professional procedures.

Answers to these questions will determine whether the product’s scientific story aligns with practical value.

Real‑World Examples and Early Adopter Response

Biotech-rich skincare products tend to attract early adopters—consumers eager to try novel science and willing to pay premium prices. Real‑world patterns show that initial adoption often depends on visible short‑term improvements (hydration, smoother texture) while sustained market acceptance requires demonstrable, longer‑term benefits and robust safety records.

Examples from the market illustrate this dynamic:

A brand launching a growth‑factor serum may generate strong initial press and influencer buzz. If users report quick hydration and visible brightness, retail sales grow. Conversely, if adverse reactions or lack of longer‑term benefits appear, the momentum stalls.
Clinics and cosmetic dermatology practices often pilot such products in‑office, pairing them with procedures. Positive clinical experiences in those settings can catalyze broader adoption.

Naples Soap Company’s retail network and wholesale channels provide a platform for Celestii to reach both direct consumers and professional outlets. The company’s success will depend on follow‑through—publishing full clinical data, ensuring manufacturing transparency and collecting longitudinal user experience.

What Dermatologists and Scientists Will Likely Want to See

Medical professionals evaluating Celestii will focus on rigorous evidence and safety parameters. The following items would strengthen the scientific case:

Detailed study reports submitted for peer review and publication.
Independent replication of clinical results by academic or clinical dermatology groups.
Clear compositional analysis of the biomimetic suspension: protein profiling, concentrations of key growth factors, cytokine panels and stability data.
Safety profiling: irritation and sensitization testing, microbiological challenge testing and long‑term tolerance data.
Regulatory clarity: statements on whether the product is positioned as a cosmetic, a cosmeceutical, or a therapeutic and the implications of that choice.

Access to this information would allow clinicians to assess the plausibility of the product’s mechanisms and recommend it to appropriate patients with confidence.

A Note on Language and Marketing: Reading Between the Lines

Marketing language in skincare often blends scientific terms with aspirational phrasing; discerning the operational meaning behind that language is crucial. Words like “stem cell” and “biomimetic” carry scientific weight but are not legally or scientifically standardized in consumer marketing.

Here are practical pointers for interpreting such language:

“Stem cell‑derived” vs. “stem cell”: The former typically means cell‑derived factors; the latter can imply presence of cells. Clarify which applies.
“3‑D cultured”: This denotes culture method but not necessarily composition. Ask if the final product contains 3‑D cell aggregates or just the molecules they secreted.
“Clinically validated”: Request the full clinical protocol and results rather than relying on summarized percentages.

Brands that pair strong claims with detailed scientific documentation differentiate themselves from those relying solely on evocative terminology.

Final Observations on Potential and Prudence

Celestii represents a clear attempt to bridge advanced cell‑culture science and consumer skincare. The use of a NASA‑derived bioreactor as a provenance story adds interest; the reported clinical improvements are promising. Yet important questions remain unanswered in the initial announcement—particularly around cell sourcing, whether viable cells are present in the finished product, methodological details of the clinical testing and comprehensive safety data.

For consumers, the decision to adopt such products rests on transparency and evidence. For Naples Soap Company, the next imperative is to provide the scientific details that convert marketing claims into verifiable advantages: publish the clinical data, disclose the composition and stability of the biomimetic suspension, and document safety and manufacturing controls.

If Celestii delivers reproducible outcomes and maintains rigorous safety standards, it could mark a meaningful step in the commercialization of biotechnologies for everyday skincare. If not, it will join a long list of novel but poorly substantiated beauty launches. Either way, the product underlines that biotech continues to reshape the contours of the cosmetic market—forcing consumers, clinicians and regulators to scrutinize what “science‑backed” truly means.

FAQ

Q: What exactly is Celestii™? A: Celestii™ is a premium skincare line launched by Naples Soap Company that centers on a proprietary biomimetic suspension derived from 3‑D stem cell cultures grown in a zero‑gravity bioreactor. The flagship Face Serum combines that suspension with polyglutamic acid, multi‑molecular hyaluronic complexes and botanical extracts for hydration, firmness and dark‑circle reduction, according to the company.

Q: Does the serum contain live stem cells? A: The company’s press release does not explicitly state whether the final product contains viable cells or only cell‑derived factors (conditioned media/secretome). Most topical products use acellular extracts to avoid the regulatory, safety and logistic challenges of incorporating live mammalian cells. Consumers should request clarification from the company on this point.

Q: How does zero‑gravity bioreactor technology relate to skincare? A: Zero‑gravity or rotating bioreactors simulate microgravity to allow cells to grow in three dimensions. Cells cultured in 3‑D conditions often secrete a different, and sometimes richer, profile of biomolecules—growth factors, cytokines and matrix proteins—that can be harvested and formulated into topical products. These secreted factors are the basis for claims about biological signaling and tissue‑supportive effects.

Q: Are the clinical results credible? A: Naples Soap Company cites a controlled study by AMA Laboratories reporting up to 161% hydration increase, 42% improvement in firmness/elasticity and up to 57% reduction in dark circles. These figures are notable but the press release omits key methodological details—sample size, study duration, statistical significance, control conditions and safety outcomes. The full study report is necessary to independently evaluate credibility.

Q: Is Celestii regulated by the FDA? A: In the United States, products marketed for cleansing, moisturizing and improving appearance typically fall under cosmetic regulation. If the product makes claims that it treats or prevents disease or modifies physiological function, regulators might classify it differently. If Celestii contains live cells or is marketed with therapeutic claims, additional regulatory scrutiny would apply. Consumers should check labeling and company statements for regulatory positioning.

Q: Who should use Celestii Face Serum? A: The brand positions the serum for mature, dehydrated or environmentally stressed skin. Individuals with sensitive skin conditions—eczema, rosacea—or those on prescription topical therapies should consult a dermatologist before adding a biotech‑derived serum. Perform a patch test before widespread use.

Q: How should the serum be incorporated into a skincare routine? A: Apply after cleansing and before moisturizer or sunscreen. Its lightweight texture reportedly makes it suitable under makeup and SPF. If using retinoids or other active treatments, consult a dermatologist to plan timing and avoid irritation.

Q: Where can I buy Celestii? A: The product is available through Naples Soap Company’s website (naplessoap.com) and at the company’s Florida retail locations. The press release also indicates distribution through the company’s wholesale channels.

Q: How can consumers verify the product’s claims? A: Request the complete clinical study report, full ingredient disclosure, manufacturing and stability data, and independent third‑party testing results. Review dermatologist commentary and independent consumer reviews. Transparency on sourcing and testing is the clearest signal of credibility.

Q: What should investors know about Naples Soap Company’s move into biotech skincare? A: The Celestii launch positions the company in a higher‑margin, science‑focused segment of the market. Investors should monitor sales performance, distribution gains in medical or professional channels, and the company’s transparency around clinical data and manufacturing. The company’s public statements also include forward‑looking cautionary language typical of publicly traded firms.

For additional detail on product composition, study protocols or procurement for professional evaluation, contact Naples Soap Company directly or consult a licensed dermatologist for personalized advice.